Literature DB >> 22262176

Ribosomal stress induces L11- and p53-dependent apoptosis in mouse pluripotent stem cells.

Lucia Morgado-Palacin1, Susana Llanos, Manuel Serrano.   

Abstract

Ribosome biogenesis is the most demanding energetic process in proliferating cells and it is emerging as a critical sensor of cellular homeostasis. Upon disturbance of ribosome biogenesis, specific free ribosomal proteins, most notably L11, bind and inhibit Mdm2, resulting in activation of the tumor suppressor p53. This pathway has been characterized in somatic and cancer cells, but its function in embryonic pluripotent cells has remained unexplored. Here, we show that treatment with low doses of Actinomycin D or depletion of ribosomal protein L37, two well-established inducers of ribosomal stress, activate p53 in an L11-dependent manner in mouse embryonic stem cells (ESCs) and in induced pluripotent stem cells (iPSCs). Activation of p53 results in transcriptional induction of p53 targets, including p21, Mdm2, Pidd, Puma, Noxa and Bax. Finally, ribosomal stress elicits L11- and p53-dependent apoptosis in ESCs/iPSCs. These results extend to pluripotent cells the functionality of the ribosomal stress pathway and we speculate that this could be a relevant cellular checkpoint during early embryogenesis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22262176     DOI: 10.4161/cc.11.3.19002

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  19 in total

1.  PAF53 is essential in mammalian cells: CRISPR/Cas9 fails to eliminate PAF53 expression.

Authors:  Lawrence I Rothblum; Katrina Rothblum; Eugenie Chang
Journal:  Gene       Date:  2016-12-29       Impact factor: 3.688

Review 2.  Ribosomal proteins: functions beyond the ribosome.

Authors:  Xiang Zhou; Wen-Juan Liao; Jun-Ming Liao; Peng Liao; Hua Lu
Journal:  J Mol Cell Biol       Date:  2015-03-03       Impact factor: 6.216

3.  Human rpL3 induces G₁/S arrest or apoptosis by modulating p21 (waf1/cip1) levels in a p53-independent manner.

Authors:  Annapina Russo; Davide Esposito; Morena Catillo; Concetta Pietropaolo; Elvira Crescenzi; Giulia Russo
Journal:  Cell Cycle       Date:  2012-12-19       Impact factor: 4.534

Review 4.  Targeting the ubiquitin-mediated proteasome degradation of p53 for cancer therapy.

Authors:  Tiffany Devine; Mu-Shui Dai
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

5.  Functional analysis of a novel glioma antigen, EFTUD1.

Authors:  Katsuya Saito; Yukihiko Iizuka; Shigeki Ohta; Satoshi Takahashi; Kenta Nakamura; Hideyuki Saya; Kazunari Yoshida; Yutaka Kawakami; Masahiro Toda
Journal:  Neuro Oncol       Date:  2014-07-11       Impact factor: 12.300

Review 6.  p53 as an intervention target for cancer and aging.

Authors:  Paul Hasty; Barbara A Christy
Journal:  Pathobiol Aging Age Relat Dis       Date:  2013-10-08

Review 7.  Translational control of stem cell function.

Authors:  James A Saba; Kifayathullah Liakath-Ali; Rachel Green; Fiona M Watt
Journal:  Nat Rev Mol Cell Biol       Date:  2021-07-16       Impact factor: 94.444

8.  Ribosomal proteins RPL37, RPS15 and RPS20 regulate the Mdm2-p53-MdmX network.

Authors:  Lilyn Daftuar; Yan Zhu; Xavier Jacq; Carol Prives
Journal:  PLoS One       Date:  2013-07-16       Impact factor: 3.240

9.  Adiponectin receptor-mediated signaling ameliorates cerebral cell damage and regulates the neurogenesis of neural stem cells at high glucose concentrations: an in vivo and in vitro study.

Authors:  J Song; S M Kang; E Kim; C-H Kim; H-T Song; J E Lee
Journal:  Cell Death Dis       Date:  2015-08-06       Impact factor: 8.469

10.  Glycosyltransferase ST6GAL1 contributes to the regulation of pluripotency in human pluripotent stem cells.

Authors:  Yu-Chieh Wang; Jason W Stein; Candace L Lynch; Ha T Tran; Chia-Yao Lee; Ronald Coleman; Adam Hatch; Victor G Antontsev; Hun S Chy; Carmel M O'Brien; Shashi K Murthy; Andrew L Laslett; Suzanne E Peterson; Jeanne F Loring
Journal:  Sci Rep       Date:  2015-08-25       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.